Relevance of Helicobacter pylori virulence factors for vaccine development

Luz del Carmen Hernández-Hernández, MS,(1) Eduardo César Lazcano-Ponce, PhD,(2) Yolanda López-Vidal, PhD,(3) Germán Rubén Aguilar-Gutiérrez, PhD(1)


Abstract
Helicobacter pylori infection increases the risk for a wide spectrum of clinical outcomes, ranging from peptic ulcer disease to gastric cancer. However, the infection induces gastric and duodenal ulceration or gastric cancer in only a minority of infected subjects because H. pylori strains are genetically diverse and express different virulence factors. Individuals infected with strains that express these virulence factors probably develop severe diseases such as gastric cancer. Nevertheless, the ancient relationship between H. pylori and humans suggests that some strains could be beneficial to human health, which means that generalized administration of antibiotic therapy could eventually cause problems. The development of vaccines based on virulence factors that provide long-term protection is the best strategy for control and/or elimination of pathogenic strains. The different immunization schemes and formulations designed to evaluate the vaccines based on virulence factors in animal models have offered promising results. However, it is necessary to determine whether or not these results can be reproduced in humans. This article reviews recent vaccination studies that explore this possibility: oral vaccines using urease or inactivated whole cells plus LT as adjuvant and urease expressed in Salmonella spp. vectors, as well as a parenteral multicomponent vaccine plus aluminum hydroxide as adjuvant. Although these studies have achieved limited success, they have established support for the development of an effective vaccine against this infection.

Key words: Helicobacter pylori; virulence factors; gastric cancer; vaccines

(1) Centro de Investigación sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, México.
(2) Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, México.
(3) Facultad de Medicina, Universidad Nacional Autónoma de México. México DF, México.

Received on: July 28, 2008 • Accepted on: January 19, 2009
Address reprint requests to: Dr. Germán Rubén Aguilar Gutiérrez. Dirección de Área de Enfermedades Crónicas y Cáncer, Centro de Investigación sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública. Av. Universidad 655, col. Santa María Ahuacatitlán, 62100, Cuernavaca, Morelos, México. E-mail: graguila@insp.mx

salud pública de méxico / vol. 51, suplemento 3 de 2009 S447
Helicobacter pylori is a gram-negative and microaerophilic bacterium that was isolated for the first time by Marshall and Warren in 1983 after extended incubation of pure culture from a human gastric mucosa biopsy.1,2 This discovery and subsequent studies radically changed existing knowledge of gastroenterology and medical microbiology. As a result of this important contribution to biological science, these Australian researchers were awarded the Nobel Prize in Physiology or Medicine in 2005.

Epidemiology

H. pylori infection constitutes an important worldwide public health problem because it is estimated that 50% of the human population is chronically infected by this pathogen. The prevalence of the infection can vary widely between and within population groups and is attributed to different socioeconomic conditions as well as basic sanitation. In fact, there is an inverse relationship between prevalence and socioeconomic conditions.4,5 The most probable route of transmission from the stomach of one person to another has not yet been clearly identified. The most widely accepted hypothesis suggests direct person to person transmission from the stomach of one person to another. The fecal-oral route is another proposed means of transmission, based on the cultures of H. pylori from the faeces of children and adults with dyspepsia and the identification of H. pylori and enteropathogenic bacteria in water sources for human consumption.6

Associations between H. pylori infection and different clinical manifestations

The chronic presence of H. pylori in gastric mucosa activates the inflammatory response by stimulating the production of cytokines by the epithelial cells.10 This inflammation generates an active chronic gastritis that can progress to gastric atrophy, metaplasia and dysplasia, conditions associated with the development of lymphoma and gastric adenocarcinoma.11,12 Although spontaneous clearance of the infection is uncommon, most individuals infected with H. pylori are asymptomatic. The percentage of people developing serious illnesses such as peptic ulcer disease is 15 to 20%, and less than 1% develops gastric adenocarcinoma. It is not clear whether the natural history of H. pylori evolves differently in different parts of the world. Nevertheless, there is now much evidence that this organism has been part of normal human microbiota since time immemorial and that it has been evolving, which suggests that the elimination of H. pylori may have risks as well as benefits for human health. Eradication of H. pylori may remove some beneficial bacterial strains and may provoke esophageal disease or gastric cancer at the cardia.13

H. pylori virulence factors

The availability of three independent sequences of the H. pylori genome has allowed for rapid advance in knowledge about the bacterium’s mechanisms of virulence, which has increased our understanding of the molecular genetic basis for the pathogenesis of H. pylori.13 Certain H. pylori strains are associated with different virulence factors that contribute in dissimilar ways to gastric mucosal damage; among them are factors known to be required for the colonization and survival of H. pylori in the human stomach.15 To date, scientists have identified several H. pylori virulence factors that confer protection against H. pylori infection or assist in eradicating an already established infection in the murine models. For these reasons, different virulence factors of H. pylori are being used for the development of an effective human vaccine against this infection.16

Urease

Urease is a multimeric complex made up of six protein subunits of UreA and six of UreB, with two nickel ions in each UreB subunit. H. pylori produces a large amount of this enzyme to catalyze the hydrolysis of the urea in ammonium and carbon dioxide; the ammonium produced neutralizes the pH of the area surrounding the microorganism, allowing it to evade the bactericidal properties of the hydrochloric acid of the stomach and to initiate the process of gastric mucosal colonization.17 Mutant strains of H. pylori negative for this enzyme are incapable of infecting the gastric epithelium of mice.18 For this reason, and because it is a protein that is widely conserved among the various strains of H. pylori, urease has been used as an antigenic component of potential vaccines in human tests.

Vacuolating cytotoxin (VacA)

VacA is another virulence factor that is actively secreted into the adjacent tissue where it produces gastric epithelial damage.19 The vacA gene is present in all H. pylori strains, but the active toxin is produced by 50% isolated bacteria from clinical cases and is epidemiologically associated with various gastroduodenal diseases.20 In
vitro, this toxin induces the alteration of vesicular traffic in eukaryote cells after being activated through exposure to acid or alkaline pH, which leads to the formation of large vacuoles containing late endosomal and lysosomal markers that cause cellular damage.\textsuperscript{21} It also inhibits the stimulation of T-lymphocytes, interfering with the processing of specific peptides in the antigen-presenting cells, which is an important part of H. pylori’s survival strategy and contributes significantly to its chronic establishment in the human stomach.\textsuperscript{22,23} The VacA gene has a variable structure in two regions: the mid-region, which could be type m1 (subtype a) or m2 (subtype a or b); and the other, the second half of the signal sequence, which could be type s1 (subtype a, b and c) or s2. The structure of the 50% isolated bacteria from the VacA gene is a mosaic with all possible combinations of these two regions, giving rise to different types of alleles. This analysis has allowed an association between the specific VacA genotype and the different clinical outcomes.\textsuperscript{24,25}

### The protein CagA and the cag pathogenicity island

Equally important is the cytotoxin-associated protein (CagA), present in approximately 80% of the H. pylori strains. CagA is one of the proteins produced by the cag pathogenicity island (cag PAI).\textsuperscript{26,27} cag PAI is a DNA segment of approximately 40 kb that codifies for about 30 proteins.\textsuperscript{28,29} This portion of DNA was probably acquired by horizontal transfer from an unknown source.\textsuperscript{30} Analysis of its genetic sequence has demonstrated that several of its genes encode subunits of the bacterial type IV secretion system (T4SS), which is an extracellular structure in the shape of a tube anchored to the internal membrane of the bacterium and specializes in the transfer of nucleic acids and/or proteins to extracellular space or to the inside of other cells.\textsuperscript{31} H. pylori uses it for the translocation of the CagA protein to the inside of the gastric epithelium cells, where it is phosphorylated in different tyrosine phosphorylation motifs (TPMs). The presence of differences in the TPMs is associated with different degrees of gastric atrophy and the risk of developing gastric cancer.\textsuperscript{32-34} Phosphorylated CagA interferes with various physiological transduction signals in the host cell and causes pathological cellular responses such as increased cellular mobility and massive polymerization of actin, which causes cellular elongation.\textsuperscript{35} The T4SS is also implicated in the transportation of H. pylori’s peptidoglycan inside the gastric epithelium cells since the elimination of its function significantly reduces the accumulation of this compound, thereby inhibiting the activation of the nuclear transcription factor kappa B (NF-kB) by Nod1 and the secretion of interleukin 8 (IL-8).\textsuperscript{36}

### The protein HP-NAP

The Helicobacter pylori neutrophil-activating protein (HP-NAP) is a multimeric protein of 150 kDa that is present in all strains but with a variable level of expression. HP-NAP exhibits chemotactic properties for neutrophils and monocytes and contributes substantially to their massive infiltration, high production of reactive oxygen radicals, and adhesion to gastric endothelium cells, which contributes to the chronic inflammation of the gastric mucosa.\textsuperscript{37,38} HP-NAP promotes Th1 immune response by increasing the production of IL-12 in monocytes and neutrophils.\textsuperscript{39} During identification of immunodominant antigens in two-dimensional gels of the H. pylori G27 strain, it was found that this protein is strongly recognized by serum of infected patients with different gastric pathologies.\textsuperscript{40} Also, mice vaccinated with this protein present protection against subsequent infection, which suggests that this virulence factor is an excellent candidate for the development of vaccines.\textsuperscript{41}

### Development of vaccines

A large number of animal models, including rodents, ferrets, gnotobiotic pigs, monkeys, dogs and cats have been used to determine the feasibility of development of an effective vaccine against H. pylori. The most frequently used animal model has been the murine because it was in these animals that the protective immune response by oral vaccination against Helicobacter felis was demonstrated and because this model has also been particularly successful in assays of H. pylori infection that reproduce human infection.\textsuperscript{42} Thus the murine model has allowed the experimentation of prophylactic and therapeutic vaccines containing different antigens, including inactive whole cells, bacterial lysates and various recombinant antigens which, when administered by a mucosal route (oral/intranasal), have resulted in high percentages of protection against infection or curing of the disease.\textsuperscript{43} However, in order for the vaccine antigens to be effective by this route, they must be administered in combination with a mucosal adjuvant that stimulates the immune system and favors the humoral and cellular responses.\textsuperscript{44,45} The mucosal adjuvants most used in mice are cholera toxin (CT) and the thermolabile toxin (LT) of Escherichia coli. However, CT is too toxic to be given to humans, and the use of LT is also limited because it induces diarrhea.\textsuperscript{46} Nevertheless, the feasibility of inducing therapeutic or prophylactic immune responses against H. pylori by vaccination in animal models has stimulated intense research activity to determine whether or not these promising results can be reproduced in humans. Table I summarizes the clinical trials in human volunteers implemented for this purpose.
<table>
<thead>
<tr>
<th>Antigens</th>
<th>Adjuvant/vector</th>
<th>Delivery route</th>
<th>Sample size</th>
<th>Infection status</th>
<th>Humoral response observed</th>
<th>Cellular response observed</th>
<th>Conclusions</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>rUreAB</td>
<td>N/D</td>
<td>Oral</td>
<td>12</td>
<td>Asymptomatic infection</td>
<td>N/D</td>
<td>N/D</td>
<td>Urease is tolerated but does not change the course of the infection course.</td>
<td>Kreiss et al ^46</td>
</tr>
<tr>
<td>rUreAB</td>
<td>LT</td>
<td>Oral</td>
<td>26</td>
<td>Asymptomatic infection</td>
<td>Serum-IgA and IgA-ASC</td>
<td>N/D</td>
<td>Urease with LT is immunogenic and does not produce adverse side effects.</td>
<td>Michteri et al ^49</td>
</tr>
<tr>
<td>rUreAB</td>
<td>Salmonella enterica sero-var Typhi (Ty1033)</td>
<td>Oral</td>
<td>8</td>
<td>Without infection</td>
<td>Not detected</td>
<td>N/D</td>
<td>The urease constitutively expressed within Ty1033 lacks immunogenicity. Multiple oral doses may be required to engender detectable mucosal and systemic antibody responses.</td>
<td>DiPetrillo et al ^55</td>
</tr>
<tr>
<td>rUreAB</td>
<td>Salmonella enterica sero-var Typhimurium (LH1160)</td>
<td>Oral</td>
<td>6</td>
<td>Without infection</td>
<td>IgG and IgA</td>
<td>N/D</td>
<td>The single oral dose of S. enterica sero-var Typhimurium expressing H. pylori urease resulted in detectable immune responses to the vectored antigen in a more sensitive assay.</td>
<td>Angelakopoulos et al ^56</td>
</tr>
<tr>
<td>rUreAB</td>
<td>LT</td>
<td>Oral</td>
<td>23 and 18</td>
<td>In D-R^4 with and without infection and in CAT^5 Asymptomatic infection</td>
<td>Serum-IgG and IgA and secretory IgA</td>
<td>Lymphocytes proliferation and IFN-γ production</td>
<td>Produces simulate secretory humoral response against urease in the infected group without eradicating the infection. There is cellular response and IFN-γ production in non-infected volunteers.</td>
<td>Kotloff et al ^52</td>
</tr>
<tr>
<td>rUreAB</td>
<td>Salmonella enterica sero-var Typhi Ty21a (pDB1)</td>
<td>Oral</td>
<td>12</td>
<td>Without infection</td>
<td>Not detected</td>
<td>T-cell response</td>
<td>The recombinant Salmonella vaccine is safe and can induce weak but detectable cellular responses to H. pylori in same volunteers.</td>
<td>Bumann et al ^57</td>
</tr>
<tr>
<td>rUreAB</td>
<td>LT</td>
<td>Oral</td>
<td>42</td>
<td>Without infection</td>
<td>Serum-IgG and IgA, IgA-ASC and IgG-ASC</td>
<td>Variable lymphocytes production</td>
<td>Confirms safety of urease. LT preserves its adjuvant activity in low doses with minimal adverse effects.</td>
<td>Banerjee et al ^58</td>
</tr>
<tr>
<td>rUreAB</td>
<td>LT</td>
<td>Rectal</td>
<td>18</td>
<td>Without infection</td>
<td>IgG, IgA and IgA-ASC</td>
<td>Lymphocytes proliferation</td>
<td>Weak response against urease but strong against LT. Established the safety of adjuvant by rectal route.</td>
<td>Sougioultzis et al ^59</td>
</tr>
<tr>
<td>rUreAB</td>
<td>LT</td>
<td>Oral</td>
<td>5</td>
<td>Without infection</td>
<td>Secretory IgA-ASC</td>
<td>N/D</td>
<td>Evidence of a specific immune response in gastric tissue in volunteers not infected with H. pylori after an oral immunization.</td>
<td>Losonsky et al ^60</td>
</tr>
<tr>
<td>rUreAB</td>
<td>CagA, VacA and HP-NAP</td>
<td>Parenteral</td>
<td>57</td>
<td>Without infection</td>
<td>Antibodies</td>
<td>Lymphocytes and IFN-γ production</td>
<td>The majority of volunteers had humoral and cellular response against three antigens months after immunization.</td>
<td>Ruggiero et al ^61</td>
</tr>
<tr>
<td>rUreAB</td>
<td>Salmonella enterica sero-var Typhi Ty21a (pDB1)</td>
<td>Oral</td>
<td>13</td>
<td>Without infection</td>
<td>Not detected</td>
<td>Lymphocytes and IFN-γ production</td>
<td>This study confirms that oral vaccination with S. sspTy21a (pDB1) is capable of inducing cellular immune response to the vectored urease.</td>
<td>Metzger et al ^62</td>
</tr>
</tbody>
</table>

^4rUreAB: Recombinant urease
^5ASC: Antibody secretory cells
^6D-R: Doses-response assay
^7CAT: Clinical aleatorized trial
^8AE: Adverses events
Recombinant UreAB (rUreAB) Vaccine and thermolabil toxin of *E. coli* (LT) as a mucosal adjuvant

Recombinant urease has been shown to produce protective and curative effects against the *H. felis* infection in murine models. However, it also generates an inflammatory process in the gastric corpus after prophylactic immunization. For this reason, Kreiss and collaborators proposed testing the effect of this protein in a double-blind, random phase one clinical trial on 12 healthy adults with asymptomatic *H. pylori* infection. They demonstrated that the oral administration of the recombinant urease was well tolerated. However, it is not capable of eradicating the infection in the absence of a mucosal adjuvant. In a second study that was randomized, double-blind and placebo-controlled, Michetti and coworkers tested four weekly oral doses of the urease in combination with the mucosal adjuvant LT in 26 asymptomatic volunteers. This improved vaccine formulation did not eradicate the infection either. However, it induced an increase of antiurease serum IgA titles related to the quantity of administered antigen and a significant decrease in gastric bacterial density (Table I). The only adverse side effect of this vaccine formulation was diarrhea attributed to the heat-labile enterotoxin. However, its incidence and severity decreased with subsequent doses in a pattern consistent with the development of the protective immune response against the adjuvant. In a third study with the same design as the previous clinical trial, 42 healthy adults received four 60 mg doses of recombinant *H. pylori* urease in soluble or in encapsulated form, given with different quantities of LT ranging from 0 to 2.5 µg, administered at day 1, 8, 29, and 57.

The results of this study demonstrated that LT may retain the mucosal adjuvant properties at a dose of 2.5 µg, with minimal side effects. In this formulation, the induction of the humoral and cellular immune responses against the recombinant protein were similar to those observed during their previous study with higher doses of LT. Interestingly, this included activated T lymphocytes and memory cells (Table I). Encapsulated urease, which is acid resistant, may be more capable of inducing lymphocyte response than the soluble form. Finally, these authors tested the safety and adjuvant efficacy of LT administered in the rectum together with rUreAB in a randomized, double-blind, ascending dose study, in which they administered 60 mg of rUreAB either with 5 or 25 µg of LT or without LT in three doses distributed over one month to 18 healthy individuals. The immunization scheme was well tolerated, although it induced a low humoral immune response against the recombinant urease among 12 vaccinated volunteers: two (16.7%) developed anti-urease IgG antibodies, one (8.3%) developed anti-urease IgA antibodies and three (25%) showed-specific IgA+ antigen secreting cells, while the lymphoproliferation responses were neither uniform nor vigorous.

**Vaccine with inactivated *H. pylori* whole-cell and thermolabil toxin LT<sub>R192G</sub> of *E. coli* as a mucosal adjuvant**

The administration of inactivated *H. pylori* whole-cells through the mucosa is another approach that has been explored. Kotloff and collaborators report a vaccine formulation based on chemically inactivated *H. pylori* whole-cell (HWC) with or without the genetically modified LT variant, LT<sub>R192G</sub>, with reduced toxicity as a mucosal adjuvant. Initially, they tested the security and immunogeneity of increasing inocula of HWC, coadministered with 25 µg of LT<sub>R192G</sub> in a dose-response study of 23 volunteers with or without infection. Afterwards, a randomized, double-blind, placebo-controlled study was conducted in a new group in which 18 *H. pylori*-infected volunteers received in three doses one of the following combinations: 2.5 X 10<sup>10</sup> HWC plus placebo-adjuvant; placebo-vaccine plus 25 µg of LTR192G; placebo-vaccine plus placebo-adjuvant; or 2.5 X 10<sup>10</sup> HWC plus 25 µg of LT<sub>R192G</sub>. Although there was no evidence that vaccination with inactivated HWC is capable of eradicating *H. pylori* infection, both the infected and uninfected volunteers presented significant rises in mucosal (fecal and salivary) anti-HWC IgA antibodies after being inoculated with 2.5 X 10<sup>10</sup> HWC plus 25 µg of LT<sub>R192G</sub>. Furthermore, in the majority of the non-infected individuals, there was an increase in gamma interferon (IFN-γ) production and lymphoproliferative response. It was also observed that adverse effects of the immunization were attributed to the toxicity of LT<sub>R192G</sub>. In a later study, the same vaccine formulation was administered in three doses to five non-infected volunteers. Two of these individuals presented detectable LT<sub>R192G</sub> and HWC IgA antibody secretion cell gastric responses, with the duodenal response greater than that of the antrum (Table I). This is the first evidence of this type of response in the mucosa of healthy individuals after an oral immunization.

**Vaccines with rUreAB with attenuated live vectors as adjuvants**

The oral administration of attenuated bacteria of the genus *Salmonella* represents an appealing option to be used as live bacterial vectors for the delivery of heterologous
antigens. Thus some research groups have explored this form of immunization as an alternative to prevent H. pylori infection. The first evaluation of the safety and immunogeneity of rUreAB of H. pylori using the Ty800 strain of Salmonella enterica serovar Typhi attenuated by the elimination of the phoP/phoQ regulon genes was carried out by DiPetrillo and collaborators. They engineered this Salmonella strain to constitutively express the subunits A and B of H. pylori urease to obtain the strain Ty1033. Later they administered a single oral dose of this strain at a concentration of ≥10^10 colony-forming units (CFU) in seven healthy volunteers, while an eighth received two doses three months apart. Two of the eight volunteers experienced diarrhea as a side effect, which was attributed to the live bacterial vector. All of the volunteers developed strong serological and mucosal immune responses to the S. typhi antigens, but none of them developed any of these responses to the vectored urease, including the three volunteers who received an oral booster vaccination with recombinant UreAB and LT two weeks after the first oral immunization. In an attempt to further define the variable for engendering immune responses to vectored antigens in humans, Angelakopoulos and collaborators carried out another study using an attenuated strain of S. enterica serovar Typhimurium (phoP/phoQ regulon deleted) that constitutively expressed UreAB.

Six volunteers were vaccinated prophylactically with 5-8 x 10^7 CFU of this strain. Two of them presented fever without other serious side effects, while five presented antibodies against the vector. In this case, the analysis of the vaccine-specific IgA and IgG release by high-density cultured peripheral mononuclear blood cells into culture medium was used as a more sensitive assay for immunoglobulins detection, which allowed observation of detectable immune responses to urease in 50% of the inoculated subjects. Two years later, another group carried out a clinical test with twelve healthy volunteers. Nine received the common live typhoid fever vaccine Salmonella enterica serovar Typhi Ty21a that constitutively expressed UreAB, Ty21a (pDB1), and three received only the Salmonella Ty21a strain in three doses of 6, 7 and 9 x 10^9 bacteria each. In 83% (10/12) of the volunteers, a humoral and cellular immune response was detected against the vector, while only 33% (3/9) of the vaccinated volunteers presented a weak but detectable cellular response to urease, and 22% (2/9) showed a cellular response of IFN-γ production and no detectable humoral response. This suggests that this type of vaccination could be adapted to induce efficient protection against the H. pylori infection. The patients who presented a cellular response against the urease had been previously immunized with Ty21a. To evaluate whether preexisting immunogeneity to the vector increases the response to the recombinant antigen, these authors designed a second clinical test in which 13 volunteers previously vaccinated with Salmonella received a treatment of three doses of 1-2 x 10^10 live bacteria. Four received the S. typhi Ty21a strain and the other nine received the Ty21a (pDB1) vaccine that expresses the urease subunits. This study showed that the majority (5/9) of the volunteers immunized with the Ty21a (pDB1) vaccine presented a cellular immune response against the urease, similar to the previous study (Table I). Finally, the authors concluded that prevaccination does not increase the response ranges to the recombinant protein or the secondary effects induced by the vector. Parenteral vaccination has been shown to provide good protection in animal models against H. pylori infection. However, in the majority of the cases, the vaccines tested consisted of bacterial lysates instead of well-defined recombinant proteins. The first tests were based on the vaccination model against pertussis and showed that effective immunity is achieved through the combination of participant antigens in different aspects of the infection’s pathogenesis. Thus a multicomponent intramuscular vaccine was developed based on the recombinant proteins VacA, CagA and HP-NAP, using aluminum hydroxide as an adjuvant. These studies reported, in a preliminary way, that the vaccine did not show adverse effects in humans and induced the production of antibodies and cellular responses against the three antigens in the majority of the 57 participants at a detectable level for several months (Table I). This demonstrated the immunoreactivity and safety of this vaccine. However, published results that demonstrate the effectiveness of this vaccine against colonization are still pending.

**Discussion**

The administration of vaccines is an effective method to prevent morbidity and mortality caused by infectious diseases. H. pylori is associated with various gastrointestinal diseases and the different strains present a growing resistance to antibiotics all over the world. Thus the development of a vaccine is an alternative strategy for the treatment and control of this infection.

However, H. pylori studies carried out to determine the best vaccination method to induce said response are few, and their determination methodologies vary. Thus it is difficult to compare results obtained to date. (Table I). Nevertheless, these studies have established a
foundation for the development of an effective vaccine against this infection.

The first study using urease as an orally administered antigen indicated the need to use adjuvants that could induce a more efficient immune response, as with the murine model. Therefore, later studies focused on testing various adjuvants as well as vectors to stimulate a better immune response against the antigen used. However, the response was always very low compared to the adjuvant or vector. Nevertheless, these studies demonstrated the possibility of inducing a humoral response in mucosas and stimulation of T-lymphocytes and memory cells in humans.

It is not clear what type of immune response is capable of eliminating the bacterium. This would be the most important step in defining whether the ideal vaccine should be therapeutic or prophylactic. Knowledge obtained to date suggests that because of the high prevalence and early age at which the infection is acquired, testing should continue to be carried out for both alternatives. To date, the multicomponent vaccine using parenteral administration has provided the best result. However, we must not forget that this is a phase one test that cannot be considered successful until it passes the subsequent phases and is proven at the populational level. Thus, it is probable that with a greater number of studies in this direction, it will finally be possible to control the infection and decrease the clinical manifestations associated with H. pylori through vaccination.

Acknowledgments

This work was supported by CONACYT grants 37181-B and V51136-M.

References

37. Dunod WG, Nishioka H; Polenghi A; Papinutto E; Zanotte G, Nod1 responds to peptidoglycan delivered by the Helicobacter pylori. The J of Immunology 2006; 36:2258-2263.